VCaP cells were specifically selected for this purpose since they represent a unique in vitro model of human prostate cancer, expressing both wild-type AR and ERα [1]; indeed, other commonly used human prostate cancer cell lines are either negative for both receptors, only express AR, or express a mutated AR that can also bind estrogens [3,4]. This evidence concerns the gene ESR1 and prostate carcinoma.